Pursuit Vascular has raised $2.1 million in a new round of debt financing, according to an SEC filing posted today.
Maple Grove, Minn.-based Pursuit Vascular produces the ClearGueard HD end caps for hemodialysis catheters, designed to kill bacteria inside long-term hemodialysis catheters.
The caps are designed with a chlorhexidine-coated rod that extends into the catheter hub to eliminate bacteria, and can be used in place of regular end caps for a single use. The device won FDA approval in late 2013.
The $2.1 million is the maximum the company was looking for in the round, according to the SEC filing. Money in the round came from 31 unnamed sources, though the company has not yet said how it plans to spend funds in the round.
Last April, the company said it reeled in more than $5.1 million through a new equity offering. Executives disclosed the new cash infusion in a regulatory filing, though specific investors are not mentioned.
Pursuit said last February that it had secured $1.6 million in a debt and securities offering to 33 unnamed investors.
